Chimerix, Inc. (CMRX) Rating Increased to Buy at Zacks Investment Research
Chimerix, Inc. (NASDAQ:CMRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The firm currently has a $5.25 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 7.14% from the stock’s previous close.
According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
Separately, ValuEngine cut Chimerix from a “sell” rating to a “strong sell” rating in a research report on Thursday.
Chimerix (CMRX) traded up $0.14 during trading hours on Friday, hitting $4.90. The stock had a trading volume of 139,200 shares, compared to its average volume of 297,703. Chimerix has a twelve month low of $4.28 and a twelve month high of $6.64.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. equities research analysts predict that Chimerix will post -1.65 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in CMRX. Dimensional Fund Advisors LP boosted its position in shares of Chimerix by 114.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after purchasing an additional 557,927 shares during the period. Morgan Stanley boosted its position in shares of Chimerix by 203.9% in the 1st quarter. Morgan Stanley now owns 618,074 shares of the biopharmaceutical company’s stock valued at $3,944,000 after purchasing an additional 414,717 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Chimerix in the 1st quarter valued at about $1,975,000. Vanguard Group Inc. boosted its position in shares of Chimerix by 13.1% in the 1st quarter. Vanguard Group Inc. now owns 1,848,257 shares of the biopharmaceutical company’s stock valued at $11,792,000 after purchasing an additional 213,894 shares during the period. Finally, AXA boosted its position in shares of Chimerix by 284.9% in the 2nd quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock valued at $1,409,000 after purchasing an additional 191,400 shares during the period. 67.77% of the stock is owned by hedge funds and other institutional investors.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.